Case report
Open access
Sep 2026
Teclistamab in relapsed, multi-refractory acquired hemophilia A after failure of anti-CD19 CAR-T cell therapy.
A patient with relapsed acquired hemophilia A (AHA), who previously failed multiple lines of immunosuppressive therapy (IST) including autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy received teclistamab, a bispecific monoclonal antibody engaging autologous CD3-positive T cells with the B cell matur...
C. Dobbelstein, Kalin Stoyanov, Krasimira Aleksandrova et al.
· Journal of Thrombosis and Ha... · 0 citations